Clinical and biologic characteristics of ALL patients treated according to the GIMEMA LAL2000
| . | p-ERK1/2 study population, n = 131 . | P . | Nonstudy population, n = 387 . |
|---|---|---|---|
| WBC, ×109/L | <.001* | ||
| Median | 39.0 | 11.0 | |
| Range | 0.9-872.3 | 0.3-800 | |
| Age, y | NS* | ||
| Median | 36.2 | 33.6 | |
| Range | 15.4-59.9 | 14.1-59.9 | |
| Blasts, % | .001* | ||
| Median | 91 | 90 | |
| Range | 65-99 | 30-99 | |
| Sex, no. (%) | NS† | ||
| Male | 74 (56.5) | 222 (57.4) | |
| Female | 57 (43.5) | 165 (42.6) | |
| Phenotype, no. (%) | NS† | ||
| B-ALL | 95 (72.5) | 310 (80.1) | |
| T-ALL | 34 (26.0) | 72 (18.6) | |
| Biphenotypic | 2 (1.5) | 5 (1.3) | |
| Molecular characteristics, no. (%) | NS† | ||
| BCR/ABL negative | 90 (73.2) | 236 (70.4) | |
| BCR/ABL positive | 33 (26.8) | 99 (29.6) | |
| NS‡ | |||
| t(4;11) negative | 94 (94.0) | 245 (95.7) | |
| t(4;11) positive | 6 (6.0) | 11 (4.3 | |
| Pretreatment responders, no. (%) | .032† | ||
| Blasts less than 1000 | 67 (66.3) | 232 (77.1) | |
| Blasts 1000 or greater | 34 (33.7) | 69 (22.9) | |
| Response to treatment | .001‡ | ||
| % CR | 72.1% | 86.3% |
| . | p-ERK1/2 study population, n = 131 . | P . | Nonstudy population, n = 387 . |
|---|---|---|---|
| WBC, ×109/L | <.001* | ||
| Median | 39.0 | 11.0 | |
| Range | 0.9-872.3 | 0.3-800 | |
| Age, y | NS* | ||
| Median | 36.2 | 33.6 | |
| Range | 15.4-59.9 | 14.1-59.9 | |
| Blasts, % | .001* | ||
| Median | 91 | 90 | |
| Range | 65-99 | 30-99 | |
| Sex, no. (%) | NS† | ||
| Male | 74 (56.5) | 222 (57.4) | |
| Female | 57 (43.5) | 165 (42.6) | |
| Phenotype, no. (%) | NS† | ||
| B-ALL | 95 (72.5) | 310 (80.1) | |
| T-ALL | 34 (26.0) | 72 (18.6) | |
| Biphenotypic | 2 (1.5) | 5 (1.3) | |
| Molecular characteristics, no. (%) | NS† | ||
| BCR/ABL negative | 90 (73.2) | 236 (70.4) | |
| BCR/ABL positive | 33 (26.8) | 99 (29.6) | |
| NS‡ | |||
| t(4;11) negative | 94 (94.0) | 245 (95.7) | |
| t(4;11) positive | 6 (6.0) | 11 (4.3 | |
| Pretreatment responders, no. (%) | .032† | ||
| Blasts less than 1000 | 67 (66.3) | 232 (77.1) | |
| Blasts 1000 or greater | 34 (33.7) | 69 (22.9) | |
| Response to treatment | .001‡ | ||
| % CR | 72.1% | 86.3% |